The FDAs accelerated approval was supported by data from the Phase II MagnetisMM-3 study, which found that in heavily pretreated RRMM patients who had not yet received BCMA-directed therapy, Elrexfio had an overall response rate of 58%, with around 82% of responders maintaining improvements for at least nine months
Allergy (2021) 76(11):343345
Prasad, S., Achazi, K., Schade, B., Haag, R
Not only APIs but also declared excipients were analyzed, mainly by XRPD
GLP-1 receptor agonists mimic the action of a natural hormone called glucagon-like peptide-1 (GLP-1), which is released in response to eating
Owing to space considerations we apologize for not citing many important contributions to this field